{"id":"NCT02200770","sponsor":"MedImmune LLC","briefTitle":"N-MOmentum: A Clinical Research Study of Inebilizumab in Neuromyelitis Optica Spectrum Disorders","officialTitle":"A Double-masked, Placebo-controlled Study With Open-label Period to Evaluate the Efficacy and Safety of MEDI-551 in Adult Subjects With Neuromyelitis Optica and Neuromyelitis Optica Spectrum Disorders.","status":"COMPLETED","phase":"PHASE2","dates":{"start":"2015-04-01","primaryCompletion":"2018-10-26","completion":"2020-11-06","firstPosted":"2014-07-25","resultsPosted":"2019-12-26","lastUpdate":"2021-12-03"},"enrollment":231,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Neuromyelitis Optica and Neuromyelitis Optica Spectrum Disorders"],"interventions":[{"type":"DRUG","name":"Inebilizumab","otherNames":["MEDI-551"]},{"type":"OTHER","name":"Placebo","otherNames":[]}],"arms":[{"label":"Placebo/Inebilizumab","type":"PLACEBO_COMPARATOR"},{"label":"Inebilizumab/Inebilizumab","type":"EXPERIMENTAL"}],"summary":"To compare the efficacy of inebilizumab (MEDI-551) versus placebo in reducing the risk of an neuromyelitis optica/neuromyelitis optica- spectrum disorders (NMO/NMOSD) attack in participants with NMO/NMOSD.","primaryOutcome":{"measure":"Time to Adjudication Committee (AC)-Determined Neuromyelitis Optica Spectrum Disorder (NMOSD) Attack During RCP","timeFrame":"Day 1 (Baseline) through Day 197","effectByArm":[{"arm":"Placebo/Inebilizumab","deltaMin":null,"sd":null},{"arm":"Inebilizumab/Inebilizumab","deltaMin":null,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.0001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":98,"countries":["United States","Australia","Bulgaria","Canada","Colombia","Czechia","Estonia","Germany","Hong Kong","Hungary","Israel","Japan","Mexico","Moldova","New Zealand","Peru","Poland","Russia","Serbia","South Africa","South Korea","Spain","Taiwan","Thailand","Turkey (TÃ¼rkiye)"]},"refs":{"pmids":["38760098","37221052","36370634","35158461","33771837","33724534","33538237","31495497","26666258"],"seeAlso":["https://filehosting-v2.pharmacm.com/api/Attachment/Download?tenantId=80217111&amp;parentIdentifier=CD-IA-MEDI-551-1155&amp;attachmentIdentifier=ae7e7dac-afeb-4a4e-bf68-5ce2e36292b8&amp;fileName=statistical_analysis_plan_cd-ia-medi-551-1155_amendment_4-redacted_PDFA.pdf&amp;versionIdentifier="]},"adverseEventsSummary":{"seriousAny":{"events":24,"n":56},"commonTop":["Urinary tract infection","Nasopharyngitis","Headache","Arthralgia","Upper respiratory tract infection"]}}